JP2022526438A5 - - Google Patents
Info
- Publication number
- JP2022526438A5 JP2022526438A5 JP2021560265A JP2021560265A JP2022526438A5 JP 2022526438 A5 JP2022526438 A5 JP 2022526438A5 JP 2021560265 A JP2021560265 A JP 2021560265A JP 2021560265 A JP2021560265 A JP 2021560265A JP 2022526438 A5 JP2022526438 A5 JP 2022526438A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- crystalline form
- systemic mastocytosis
- mastocytosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833527P | 2019-04-12 | 2019-04-12 | |
| US62/833,527 | 2019-04-12 | ||
| US201962844575P | 2019-05-07 | 2019-05-07 | |
| US62/844,575 | 2019-05-07 | ||
| US202062990269P | 2020-03-16 | 2020-03-16 | |
| US62/990,269 | 2020-03-16 | ||
| PCT/US2020/027724 WO2020210669A1 (en) | 2019-04-12 | 2020-04-10 | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526438A JP2022526438A (ja) | 2022-05-24 |
| JP2022526438A5 true JP2022526438A5 (https=) | 2023-04-18 |
| JP7728178B2 JP7728178B2 (ja) | 2025-08-22 |
Family
ID=70476546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560265A Active JP7728178B2 (ja) | 2019-04-12 | 2020-04-10 | （ｓ）－１－（４－フルオロフェニル）－１－（２－（４－（６－（１－メチル－１ｈ－ピラゾール－４－イル）ピロロ［２，１－ｆ］［１、２，４］トリアジン－４－イル）ピペラジニル）－ピリミジン－５－イル）エタン－１－アミンの結晶形態及び製造方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US12060354B2 (https=) |
| EP (2) | EP4302761A3 (https=) |
| JP (1) | JP7728178B2 (https=) |
| CN (1) | CN113966334B (https=) |
| CA (2) | CA3296895A1 (https=) |
| DK (1) | DK3856341T3 (https=) |
| ES (1) | ES2966512T3 (https=) |
| FI (1) | FI3856341T3 (https=) |
| HR (1) | HRP20231533T1 (https=) |
| HU (1) | HUE064283T2 (https=) |
| IL (2) | IL287148A (https=) |
| LT (1) | LT3856341T (https=) |
| MA (1) | MA53759A (https=) |
| PL (1) | PL3856341T3 (https=) |
| PT (1) | PT3856341T (https=) |
| RS (1) | RS64881B1 (https=) |
| SI (1) | SI3856341T1 (https=) |
| SM (1) | SMT202300447T1 (https=) |
| TW (1) | TWI845657B (https=) |
| WO (1) | WO2020210669A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3057969T1 (sl) | 2013-10-17 | 2018-10-30 | Blueprint Medicines Corporation | Sestavki, uporabni za zdravljenje motenj, povezanih s KIT |
| ES2966512T3 (es) | 2019-04-12 | 2024-04-22 | Blueprint Medicines Corp | Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración |
| CN114341138A (zh) * | 2019-07-09 | 2022-04-12 | 桑多斯股份公司 | 口服可用的选择性kit和pdgfr激酶抑制剂的晶型 |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| WO2021183709A1 (en) | 2020-03-11 | 2021-09-16 | Teva Czech Industries S.R.O | Solid state forms of avapritinib and process for preparation thereof |
| WO2021257522A1 (en) | 2020-06-17 | 2021-12-23 | Teva Czech Industries S.R.O | Solid state forms of avapritinib salts |
| HU231413B1 (hu) * | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| AU2022231009A1 (en) | 2021-03-03 | 2023-09-21 | Blueprint Medicines Corporation | Synthetic methods and intermediates for producing compounds for treating kit- and pdgfra-mediated diseases |
| HU231755B1 (hu) * | 2022-08-11 | 2026-02-28 | Egis Gyógyszergyár Zrt. | Új avapritinib sók és előállítási eljárásaik |
| US20240382493A1 (en) * | 2023-05-18 | 2024-11-21 | Blueprint Medicines Corporation | Methods for treating systemic mastocytosis and gastrointestinal stromal tumors |
| WO2025170989A1 (en) | 2024-02-05 | 2025-08-14 | Blueprint Medicines Corporation | High-risk disease features of indolent systemic mastocytosis and methods for treating |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| JP4649046B2 (ja) | 1999-05-21 | 2011-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼのピロロトリアジン阻害剤 |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| MXPA02003436A (es) | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| PL357672A1 (en) * | 2000-03-30 | 2004-07-26 | Shionogi & Co, Ltd. | Novel process for producing fused imidazopyridine derivative and novel crystal form |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| PT1497019E (pt) | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| US7468376B2 (en) | 2003-02-27 | 2008-12-23 | Palau Pharma, S.A. | Pyrazolopyridine derivates |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006028524A2 (en) | 2004-04-29 | 2006-03-16 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| DK1973910T3 (da) | 2006-01-27 | 2013-08-12 | Shanghai Hengrui Pharm Co Ltd | Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer |
| HRP20140688T1 (hr) | 2006-07-07 | 2014-10-24 | Bristol-Myers Squibb Company | Inhibitori piroltriazin kinaze |
| US8415340B2 (en) | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| CA2716856C (en) | 2008-03-20 | 2013-02-19 | Amgen Inc. | Aurora kinase modulators and method of use |
| KR20100003912A (ko) | 2008-07-02 | 2010-01-12 | 삼성전자주식회사 | 동일 포맷의 미디어 파일 간에 미디어 정보 호환이 가능한미디어 파일을 생성하는 방법 및 장치와 미디어 파일을실행하는 방법 및 장치 |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| JP2012529512A (ja) | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011103196A1 (en) | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| EP2892534B8 (en) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX365640B (es) | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| SI3057969T1 (sl) | 2013-10-17 | 2018-10-30 | Blueprint Medicines Corporation | Sestavki, uporabni za zdravljenje motenj, povezanih s KIT |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| AR099789A1 (es) * | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| CN108026102A (zh) | 2015-07-24 | 2018-05-11 | 蓝印药品公司 | 可用于治疗与kit和pdgfr相关的病症的化合物 |
| BR112018003588A2 (pt) | 2015-08-26 | 2018-09-25 | Blueprint Medicines Corp | compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk |
| US20170119760A1 (en) | 2015-10-28 | 2017-05-04 | Ab Science | Use of masitinib for the treatment of progressive supranuclear palsy |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| CN109311889B (zh) | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
| ES2975263T3 (es) * | 2016-06-20 | 2024-07-04 | Novartis Ag | Formas cristalinas de un compuesto triazolopirimidínico |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| IL276398B2 (en) * | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| US20220010382A1 (en) | 2018-11-12 | 2022-01-13 | Blueprint Medicines Corporation | Avapritinib resistance of kit mutants |
| ES2966512T3 (es) | 2019-04-12 | 2024-04-22 | Blueprint Medicines Corp | Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración |
| CN114341138A (zh) | 2019-07-09 | 2022-04-12 | 桑多斯股份公司 | 口服可用的选择性kit和pdgfr激酶抑制剂的晶型 |
| GB201915447D0 (en) | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| TW202122089A (zh) | 2019-11-04 | 2021-06-16 | 美商纜圖藥品公司 | 肥大細胞疾病及嗜酸性病症之治療 |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
-
2020
- 2020-04-10 ES ES20722936T patent/ES2966512T3/es active Active
- 2020-04-10 DK DK20722936.0T patent/DK3856341T3/da active
- 2020-04-10 JP JP2021560265A patent/JP7728178B2/ja active Active
- 2020-04-10 LT LTEPPCT/US2020/027724T patent/LT3856341T/lt unknown
- 2020-04-10 SI SI202030328T patent/SI3856341T1/sl unknown
- 2020-04-10 PL PL20722936.0T patent/PL3856341T3/pl unknown
- 2020-04-10 EP EP23195076.7A patent/EP4302761A3/en active Pending
- 2020-04-10 CN CN202080042782.9A patent/CN113966334B/zh active Active
- 2020-04-10 HR HRP20231533TT patent/HRP20231533T1/hr unknown
- 2020-04-10 MA MA053759A patent/MA53759A/fr unknown
- 2020-04-10 FI FIEP20722936.0T patent/FI3856341T3/fi active
- 2020-04-10 HU HUE20722936A patent/HUE064283T2/hu unknown
- 2020-04-10 CA CA3296895A patent/CA3296895A1/en active Pending
- 2020-04-10 TW TW109112270A patent/TWI845657B/zh active
- 2020-04-10 PT PT207229360T patent/PT3856341T/pt unknown
- 2020-04-10 WO PCT/US2020/027724 patent/WO2020210669A1/en not_active Ceased
- 2020-04-10 SM SM20230447T patent/SMT202300447T1/it unknown
- 2020-04-10 CA CA3136707A patent/CA3136707A1/en active Pending
- 2020-04-10 EP EP20722936.0A patent/EP3856341B1/en active Active
- 2020-04-10 RS RS20231131A patent/RS64881B1/sr unknown
-
2021
- 2021-01-20 US US17/153,727 patent/US12060354B2/en active Active
- 2021-10-10 IL IL287148A patent/IL287148A/en unknown
-
2022
- 2022-12-08 US US18/077,431 patent/US12252494B2/en active Active
- 2022-12-08 US US18/077,466 patent/US11964980B2/en active Active
-
2023
- 2023-12-18 US US18/543,793 patent/US11999744B2/en active Active
-
2024
- 2024-08-12 US US18/800,215 patent/US20260116883A1/en active Pending
-
2025
- 2025-10-28 IL IL324301A patent/IL324301A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022526438A5 (https=) | ||
| JP6824409B2 (ja) | 六酸化四砒素の結晶多形を含む癌予防または治療用薬学組成物 | |
| JP2023511105A5 (https=) | ||
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| JP2010132669A (ja) | ストロンチウムラネレートのアルファー（α）−結晶形、その製造方法、及びそれを含む医薬組成物 | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| JP2022523368A5 (https=) | ||
| JP2020521732A5 (https=) | ||
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| US9957282B2 (en) | Crystalline forms of quinolone analogs and their salts | |
| EP3394070B1 (en) | Crystalline forms of quinolone analogs and their salts | |
| RU2018103172A (ru) | Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона | |
| BR112021012639A2 (pt) | Novo composto e composição farmacêutica compreendendo o mesmo para intensificar atividade anticâncer | |
| JP2024509276A5 (https=) | ||
| WO2017020869A1 (zh) | 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用 | |
| JP2020536944A5 (https=) | ||
| JP2022179783A (ja) | キノロン類似体及びその塩の結晶形 | |
| JP2020512975A5 (https=) | ||
| WO2012119653A1 (en) | Process for making crystalline form a of linezolid | |
| CN116143709A (zh) | 丹酚酸a衍生物的新晶型及其制备方法 | |
| CN109535060B (zh) | 一种刺猬通路抑制剂及其制备方法和应用 | |
| WO2017175177A1 (en) | Process for preparing oxathiazin-like compounds | |
| TW201806928A (zh) | 胺基羧酸之酸加成鹽的結晶及其製造方法 | |
| WO2025198588A1 (en) | Preparation of compound and crystalline forms thereof | |
| WO2024027695A1 (zh) | 作为her2抑制剂的化合物 |